Intramolecular Cyclization of N-Allyl Propiolamides: a Facile Synthetic Route to Highly Substituted G- Cite This: RSC Adv.,2017,7, 28407 Lactams (A Review)

Total Page:16

File Type:pdf, Size:1020Kb

Intramolecular Cyclization of N-Allyl Propiolamides: a Facile Synthetic Route to Highly Substituted G- Cite This: RSC Adv.,2017,7, 28407 Lactams (A Review) RSC Advances View Article Online REVIEW View Journal | View Issue Intramolecular cyclization of N-allyl propiolamides: a facile synthetic route to highly substituted g- Cite this: RSC Adv.,2017,7, 28407 lactams (a review) Somayeh Soleimani-Amiri,*a Esmail Vessally, b Mirzaagha Babazadeh,c Akram Hosseiniand and Ladan Edjlalic The development of simple and efficient methods for construction of substituted g-lactams is an important synthetic goal because such ring skeletons are present in numerous natural compounds that display diverse Received 15th March 2017 biological activities. Intramolecular cyclization of N-allyl propiolamides is an efficient, economic, and Accepted 4th May 2017 operationally simple strategy for the synthesis of the titled compounds. In the present review we will DOI: 10.1039/c7ra03075d discuss recent advances in the synthesis of functionalized g-lactam derivatives from these easily rsc.li/rsc-advances accessible and versatile building blocks with the emphasis on the mechanistic aspects of the reactions. Creative Commons Attribution 3.0 Unported Licence. 1. Introduction supplement that has the ability to enhance memory and learning ability. It also used as an adjunctive treatment for 2 Needless to say, g-lactams are at the heart of a number of myoclonus of cortical origin. Marizomib 3 is a naturally- medicinally and biologically important compounds, as well as occurring salinosporamide, isolated from the marine actino- a large array of natural products. For instance, brivaracetam 1, mycete Salinospora tropica. This compound is a promising drug with the brand name Briviact, is an anticonvulsant drug mar- candidate for the treatment of multiple myeloma and mantle 3,4 keted worldwide for the treatment of partial onset seizures.1 cell lymphoma. Annosqualine 4, which has good antibacterial Piracetam 2 (also known as a smart drug) is a nootropic activity, is a natural product isolated from the stems of Annona 5,6 This article is licensed under a Squamosa. Codinaeopsin 5, which was isolated from an endophytic fungus collected in Costa Rica, has signicant a Department of Chemistry, Karaj Branch, Islamic Azad University, Karaj, Iran. E-mail: 7 [email protected]; [email protected] antimalarial activity. This biological activity has made the b synthesis of g-lactams quite attractive, and a large number of Open Access Article. Published on 30 May 2017. Downloaded 9/23/2021 11:40:53 PM. Department of Chemistry, Payame Noor University, Tehran, Iran cDepartment of Chemistry, Tabriz Branch, Islamic Azad University, Tabriz, Iran straightforward and robust methods for the construction of 8–12 dDepartment of Engineering Science, College of Engineering, University of Tehran, P. O. these cores has been established. More recently, Rivas and Box 11365-4563, Tehran, Iran Somayeh Soleimani-Amiri was Esmail Vessally was born in born in Tehran, Iran, in 1975. Sharabiyan, Sarab, Iran, in She received her B.S. degree in 1973. He received his B.S. degree Pure Chemistry from Shahid in Pure Chemistry from Univer- Beheshti University, Tehran, sity of Tabriz, Tabriz, Iran, and Iran, and her M.S. degree in his M.S. degree in organic organic chemistry from Alzahra chemistry from Tehran Univer- University, Tehran, Iran, in sity, Tehran, Iran, in 1999 under 2002 under the supervision of the supervision of Prof. H. Pir- Prof. S. H. Abdi Oskooie and elahi. He completed his Ph.D. Prof. M. M. Heravi. She degree in 2005 under the super- completed his Ph.D. degree in vision of Prof. M. Z. Kassaee. 2009 under the supervision of Now he is working at Payame Prof. M. Z. Kassaee. Now she is working at Karaj Branch, Islamic Noor University as full Professor of Organic Chemistry. His Azad University as Assistant Professor. Her research interests research interests include Theoretical Organic Chemistry, new include Computational Organic Chemistry, Nano Chemistry, methodologies in organic synthesis and spectral studies of organic Synthesis of Organic Compounds. compounds. This journal is © The Royal Society of Chemistry 2017 RSC Adv.,2017,7,28407–28418 | 28407 View Article Online RSC Advances Review Ling published an interesting review paper that covers most of 2. Transition metal-catalyzed the recent advances in the synthesis of the titled compounds.12 However, synthesis of these cores through intramolecular cyclizations cyclization of simple and easily accessible N-allyl propiolamide 2.1 Palladium derivatives was omitted, while this synthetic strategy has Synthesis of g-lactams via Pd-catalyzed intramolecular cycliza- ffi recently attracted much attention because of its high e ciency, tion of propiolamide derivatives has been the subject of atom economy, and operational simplicity (Fig. 1). a number of papers. One of the earliest report on this chemistry In connection with our series of review papers on the have been published by Lu and co-workers in 1996. They synthesis of nitrogen based heterocycles from N- showed that treatment of N-allyl propiolamides 6 with the propargylamine/amide derivatives,13–22 we summarize here PdCl2(PhCN)2/CuCl2/LiCl system in acetonitrile directly gave g a variety of protocols for the synthesis of -lactam cores from corresponding a-chloromethylene-b-chloromethyl-g-lactams 7 readily accessible N-allyl propiolamides. The review is divided aer 6–40 hours at room temperature (Scheme 1). According to into two major sections. The rst section focuses exclusively on the author proposed mechanism, this transformation pro- transition metal-catalyzed cyclization of N-allyl propiolamides, ceeded via a chloropalladation/oxidative cleavage/insertion while the second covers radical promoted cyclizations. It should sequential process.23 In a closely related study, the same be noted that we have not discussed synthesis of indolinones group found that N-(30-formylallylic)propiolamides 8 were con- g (benzene-fused -lactams), since it has recently been described verted to the corresponding a-bromomethylene-b-for- in another publication.13 mylmethyl-g-lactams 9, via Pd(II)-catalyzed intramolecular cyclization using LiBr as bromide source in HOAc at room temperature (Scheme 2).24 Mirzaagha Babazadeh is Asso- In 2005, Zhu and Zhang described the rst PdCl2-catalyzed ciate Professor of Organic Chem- cis-chloropalladation-cyclization reaction of N-allyl propiola- Creative Commons Attribution 3.0 Unported Licence. 10 istry in Department of Chemistry mides. Thus, the treatment of 1,6-enyne substrates with 5 ff a at Tabriz Branch, Islamic Azad mol% of PdCl2 in HOAc at 50 Ca orded corresponding (E)- - g 11 University, Tabriz, Iran. He was halomethylene- -lactams in high isolated yields g born in Tabriz, Iran, in 1973. He (Scheme 3a). The mechanism proposed for the formation of - lactams 11 involves the key intermediate A, which underwent received his B.S. degree in 25 Applied Chemistry (1996) and dehalopalladation to produce the cyclized product. Subse- his M.S. degree in Organic quently, the same authors extended this chemistry to synthesis a g 13 Chemistry from University of of -phenylmethylene- -lactams via a beautiful Pd(0)- catalyzed tandem cyclization/Suzuki coupling reaction of N- This article is licensed under a Tabriz, Tabriz, Iran (1999) under 12 26 the supervision of Prof. A. A. allyl propiolamides with phenylboronic acid. Several cata- lysts, bases and solvents were tested, and the system Pd(PPh3)4/ Entezami and Prof. H. Namazi. 27 He completed his Ph.D. degree under the supervision of Prof. K. D. KF/toluene was found to be superior. Under optimized Open Access Article. Published on 30 May 2017. Downloaded 9/23/2021 11:40:53 PM. Safa in University of Tabriz, Tabriz, Iran (2005). His research conditions, the reaction tolerates both aryl and alkyl substituted 13 interests focus on organic synthesis, catalyst, polymer, green internal propiolamides and gave the corresponding lactams chemistry, drug delivery systems, organosilicon compounds and in high yields (Scheme 3b). nanocomposites. Akram Hosseinian was born in Ladan Edjlali was born in Ahar, Iran, in 1973. She received Tabriz, Iran, in 1960. She her B.S. degree in Pure Chem- received her B.S. degree in istry from University of Tehran, Applied Chemistry from Univer- Iran, and her M.S. degree in sity of Tabriz, Iran, and her M.S. inorganic chemistry from Tarb- degree in organic chemistry from iat Modares University, Tehran, University of Tabriz, Tabriz, Iran, in 2000 under the super- Iran, in 1993 under the super- vision of Prof. A. R. Mahjoub. vision of Prof. Y. Mirzaei. She She completed his Ph.D. degree completed his Ph.D. degree in in 2007 under the supervision of 2000 under the supervision of Prof. A. R. Mahjoub. Now she is Prof. Y. Mirzaei and Prof. S. M. working at University of Tehran Golabi. Now, she is working at as Assistant Professor. Her research interests include inorganic Islamic Azad University, Tabriz Branch as Associate Professor. Her and organic synthesis, new methodologies in nano material research interests include organic synthesis and new methodolo- synthesis. gies in organic synthesis. 28408 | RSC Adv.,2017,7,28407–28418 This journal is © The Royal Society of Chemistry 2017 View Article Online Review RSC Advances Fig. 1 Selected examples of bioactive g-lactams. Creative Commons Attribution 3.0 Unported Licence. This article is licensed under a Scheme 1 a b g Open Access Article. Published on 30 May 2017. Downloaded 9/23/2021 11:40:53 PM. Lu's synthesis of -chloromethylene- -chloromethyl- -lactams 7. trans-acetoxypalladation/b-heteroatom elimination sequential process. The author found that when the reaction was carried out in the presence of chiral nitrogen-containing ligands, an asymmetric version of this protocol with moderate enantiose- lectivity was established.28 In 2010, the same group reported an elegant approach for the synthesis of a-alkylidene-b-hydroxy-g-lactams 18 via Pd(II)- catalyzed cascade reaction of propiolamides 16 and arylboronic acids 17. The optimum conditions for this reaction utilize Pd(OAc)2 as the catalyst, bpy as ligand and DCE/H2O (20 : 1) as 0 Scheme 2 Pd(II)-catalyzed cyclization of N-(3 -formylallylic)propio- solvent.
Recommended publications
  • Mechanisms of Action of Antiepileptic Drugs
    Review Mechanisms of action of antiepileptic drugs Epilepsy affects up to 1% of the general population and causes substantial disability. The management of seizures in patients with epilepsy relies heavily on antiepileptic drugs (AEDs). Phenobarbital, phenytoin, carbamazepine and valproic acid have been the primary medications used to treat epilepsy for several decades. Since 1993 several AEDs have been approved by the US FDA for use in epilepsy. The choice of the AED is based primarily on the seizure type, spectrum of clinical activity, side effect profile and patient characteristics such as age, comorbidities and concurrent medical treatments. Those AEDs with broad- spectrum activity are often found to exert an action at more than one molecular target. This article will review the proposed mechanisms of action of marketed AEDs in the US and discuss the future of AEDs in development. 1 KEYWORDS: AEDs anticonvulsant drugs antiepileptic drugs epilepsy Aaron M Cook mechanism of action seizures & Meriem K Bensalem-Owen† The therapeutic armamentarium for the treat- patients with refractory seizures. The aim of this 1UK HealthCare, 800 Rose St. H-109, ment of seizures has broadened significantly article is to discuss the past, present and future of Lexington, KY 40536-0293, USA †Author for correspondence: over the past decade [1]. Many of the newer AED pharmacology and mechanisms of action. College of Medicine, Department of anti epileptic drugs (AEDs) have clinical advan- Neurology, University of Kentucky, 800 Rose Street, Room L-455, tages over older, so-called ‘first-generation’ First-generation AEDs Lexington, KY 40536, USA AEDs in that they are more predictable in their Broadly, the mechanisms of action of AEDs can Tel.: +1 859 323 0229 Fax: +1 859 323 5943 dose–response profile and typically are associ- be categorized by their effects on the neuronal [email protected] ated with less drug–drug interactions.
    [Show full text]
  • PR2 2009.Vp:Corelventura
    Pharmacological Reports Copyright © 2009 2009, 61, 197216 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Review Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions Jarogniew J. £uszczki1,2 Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, PL 20-090 Lublin, Poland Department of Physiopathology, Institute of Agricultural Medicine, Jaczewskiego 2, PL 20-950 Lublin, Poland Correspondence: Jarogniew J. £uszczki, e-mail: [email protected]; [email protected] Abstract: This review briefly summarizes the information on the molecular mechanisms of action, pharmacokinetic profiles and drug interac- tions of novel (third-generation) antiepileptic drugs, including brivaracetam, carabersat, carisbamate, DP-valproic acid, eslicar- bazepine, fluorofelbamate, fosphenytoin, ganaxolone, lacosamide, losigamone, pregabalin, remacemide, retigabine, rufinamide, safinamide, seletracetam, soretolide, stiripentol, talampanel, and valrocemide. These novel antiepileptic drugs undergo intensive clinical investigations to assess their efficacy and usefulness in the treatment of patients with refractory epilepsy. Key words: antiepileptic drugs, brivaracetam, carabersat, carisbamate, DP-valproic acid, drug interactions, eslicarbazepine, fluorofelbamate, fosphenytoin, ganaxolone, lacosamide, losigamone, pharmacokinetics, pregabalin, remacemide, retigabine, rufinamide, safinamide, seletracetam, soretolide, stiripentol, talampanel, valrocemide Abbreviations: 4-AP
    [Show full text]
  • Pharmaceutical Composition Comprising Brivaracetam and Lacosamide with Synergistic Anticonvulsant Effect
    (19) TZZ __T (11) EP 2 992 891 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.03.2016 Bulletin 2016/10 A61K 38/04 (2006.01) A61K 31/4015 (2006.01) A61P 25/08 (2006.01) (21) Application number: 15156237.8 (22) Date of filing: 15.06.2007 (84) Designated Contracting States: (71) Applicant: UCB Pharma GmbH AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 40789 Monheim (DE) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (72) Inventor: STOEHR, Thomas 2400 Mol (BE) (30) Priority: 15.06.2006 US 813967 P 12.10.2006 EP 06021470 (74) Representative: Dressen, Frank 12.10.2006 EP 06021469 UCB Pharma GmbH 22.11.2006 EP 06024241 Alfred-Nobel-Strasse 10 40789 Monheim (DE) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 07764676.8 / 2 037 965 This application was filed on 24-02-2015 as a divisional application to the application mentioned under INID code 62. (54) PHARMACEUTICALCOMPOSITION COMPRISING BRIVARACETAM AND LACOSAMIDE WITH SYNERGISTIC ANTICONVULSANT EFFECT (57) The present invention is directed to a pharmaceutical composition comprising (a) lacosamide and (b) brivara- cetam for the prevention, alleviation or/and treatment of epileptic seizures. EP 2 992 891 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 992 891 A1 Description [0001] The present application claims the priorities of US 60/813.967 of 15 June 2006, EP 06 021 470.7 of 12 October 2006, EP 06 021 469.9 of 12 October 2006, and EP 06 024 241.9 of 22 November 2006, which are included herein by 5 reference.
    [Show full text]
  • Antiepileptic Potential of Ganaxolone Antiepileptički Potencijal Ganaksolona
    Vojnosanit Pregl 2017; 74(5): 467–475. VOJNOSANITETSKI PREGLED Page 467 UDC: 615.03::616.853-085 GENERAL REVIEW https://doi.org/10.2298/VSP151221157J Antiepileptic potential of ganaxolone Antiepileptički potencijal ganaksolona Slobodan Janković, Snežana Lukić Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia Key words: Ključne reči: ganaxolone; epilepsies, partial; neurotransmitter ganaksolon; epilepsije, parcijalne; neurotransmiteri; agents; child; adult. deca; odrasle osobe. Introduction New anticonvulsants With its estimated prevalence of 0.52% in Europe, The drug resistant epilepsy has been recently defined by 0.68% in the United States of America and up to 1.5% in de- the International League Against Epilepsy as “a failure of veloping countries, epilepsy makes a heavy burden on indi- adequate trials of two tolerated, appropriately chosen and viduals, healthcare systems and societies in general all over used antiepileptic drug schedules (whether as monotherapies the world 1, 2. Despite long history of epilepsy treatment with or in combination) to achieve sustained seizure free- dom” 11.The mechanisms of drug resistance in epilepsy are medication, efficacy and effectiveness of available antiepi- still incompletely understood, and none of the anticonvul- leptic drugs as monotherapy were unequivocally proven in sants with current marketing authorization has demonstrated clinical trials only for partial-onset seizures in children and superior efficacy in the treatment of drug resistant epilepsy 12. adults (including elderly), while generalized-onset tonic- Using new anticonvulsants as add-on therapy lead to free- clonic seizures in children and adults, juvenile myoclonic dom from seizures in only 6% of patients with drug resistant epilepsy and benign epilepsy with centrotemporal spikes are epilepsy 13.
    [Show full text]
  • Telemetric EEG and the Rat: a Guide for Neuroscientists
    Editorial Telemetric EEG and the Rat: A Guide For Neuroscientists Jafri Malin AbdullAh1, Mohammad RAfiqul islAm2 1 Malaysian Journal of Medical Sciences, Universiti Sains Malaysia Press, Universiti Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia 2 Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia Abstract Telemetric EEG in the rat’s brain has been used for experiments which tests the effects of an antiepileptic compound on it’s antiseizures activity. A simple classification correlating epileptiform discharge and Racine’s behavioral activity is discussed. Keywords: electroencephalogram, neuroscience, rat, telemetry Animal models for seizures and epilepsy scale for the assessment of seizure intensities in have played a fundamental role in advancing our other epilepsy or seizure models is justifiable, understanding of basic mechanisms underlying given the well known relation between activated ictogenesis and epileptogenesis and have been brain part and corresponding expressed behavior instrumental in the discovery and preclinical of Sprague Dawley rats (160–350 g) which are development of novel antiepileptic drugs. suitable animals to induce status epilepticus Despite the successful development of various models and to record continuous EEG spikes and new antiepileptic drugs in recent decades, the wave discharges (4–6). search for new therapies with better efficacy and We used a total of 10 male Sprague Dawley tolerability remains an important goal (1). The and 6 Genetic Absence Epilepsy Rats from discovery and development of a new antiepileptic Strasbourg (GAERS) rats (7), four to six months drug relies heavily on the preclinical use of animal of age and weighing 187–325 g.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0021786 A1 Schenkel Et Al
    US 2011 0021786A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0021786 A1 Schenkel et al. (43) Pub. Date: Jan. 27, 2011 (54) PHARMACEUTICAL SOLUTIONS, PROCESS (86). PCT No.: PCT/EP09/524.54 OF PREPARATION AND THERAPEUTC USES S371 (c)(1), (2), (4) Date: Oct. 6, 2010 (75) Inventors: Eric Schenkel, Brussels (BE): Claire Poulain, Brussels (BE); (30) Foreign Application Priority Data Bertrand Dodelet, Brussels (BE): Domenico Fanara, Brussels (BE) Mar. 3, 2008 (EP) .................................. O8OO3915.9 Correspondence Address: Publication Classification MCDONNELL BOEHNEN HULBERT & BERG HOFF LLP (51) Int. Cl. 300 S. WACKER DRIVE, 32ND FLOOR C07D 207/27 (2006.01) CHICAGO, IL 60606 (US) (52) U.S. Cl. ........................................................ 548/SSO (73) Assignee: UCB PHARMA, S.A., Brussels (BE) (57) ABSTRACT (21) Appl. No.: 12/920,524 The present invention concerns a stable pharmaceutical solu tion, a process of the preparation thereof and therapeutic uses (22) PCT Filed: Mar. 2, 2009 thereof. US 2011/002 1786 A1 Jan. 27, 2011 PHARMACEUTICAL SOLUTIONS, PROCESS 0006 Seletracetam is effective in the treatment of epi OF PREPARATION AND THERAPEUTC lepsy. USES 0007. Until now, brivaracetam and seletracetam have been formulated in Solid compositions (film coated tablet, gran ules). 0008. However, an oral solution would be particularly desirable for administration in children and also in some adult 0001. The present invention concerns stable liquid formu patients. An injectable Solution could be advantageously used lations of 2-oxo-1-pyrrolodine derivatives, a process of the in case of epilepsy crisis. preparation thereof and therapeutic uses thereof. 0009 Moreover, administration of an oral dosage form is 0002 International patent application having publication the preferred route of administration for many pharmaceuti number WO 01/62726 discloses 2-oxo-1-pyrrolidine deriva cals because it provides for easy, low-cost administration.
    [Show full text]
  • Brivaracetam and Perampanel As Broad-Spectrum Antiseizure Drugs
    Expert Opinion on Pharmacotherapy ISSN: 1465-6566 (Print) 1744-7666 (Online) Journal homepage: https://www.tandfonline.com/loi/ieop20 Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad- spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus Laurent Maximilian Willems, Sebastian Bauer, Felix Rosenow & Adam Strzelczyk To cite this article: Laurent Maximilian Willems, Sebastian Bauer, Felix Rosenow & Adam Strzelczyk (2019): Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus, Expert Opinion on Pharmacotherapy, DOI: 10.1080/14656566.2019.1637420 To link to this article: https://doi.org/10.1080/14656566.2019.1637420 Published online: 02 Jul 2019. Submit your article to this journal View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ieop20 EXPERT OPINION ON PHARMACOTHERAPY https://doi.org/10.1080/14656566.2019.1637420 REVIEW Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus Laurent Maximilian Willems a,b, Sebastian Bauera,b, Felix Rosenowa,b and Adam Strzelczyk a,b,c aEpilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University Frankfurt, Frankfurt am Main, Germany; bLOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Frankfurt am Main, Germany; cEpilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg (Lahn), Germany ABSTRACT ARTICLE HISTORY Introduction: Antiseizure drugs (ASDs) play a central and crucial role in the treatment of epilepsy Received 11 May 2019 patients, as the majority require anticonvulsant treatment for an extended period of time.
    [Show full text]
  • Levetiracetam Inhibits Endocytosis and Augments Short-Term Depression
    ORIGINAL ARTICLES Department of Physiology and Biophysics, School of Life Sciences, Fudan University, Shanghai, China Levetiracetam inhibits endocytosis and augments short-term depression LI-MENG, LEI-XUE* Received July 5, 2018, accepted August 5, 2018 *Corresponding author: Lei-Xue, Department of Physiology and Biophysics, School of Life Sciences, Fudan University, Shanghai, China, 200438 [email protected] Pharmazie 73: 643–646 (2018) doi: 10.1691/ph.2018.8634 Levetiracetam (LEV) is an anti-epileptic drug with demonstrated efficacy against generalized seizures. Recent studies have found that LEV affects the release of neurotransmitters by binding to synaptic vesicle protein 2A (SV2A). However, the details of LEV regulation of synaptic transmission remain poorly understood. Here, we used the whole-cell patch-clamp technique to further characterize the effects of LEV on synaptic transmission at a large mammalian central synapse, the calyx of Held. Our results showed that two common forms of vesicle endocytosis, including slow and rapid endocytosis, were dramatically inhibited when slices were incubated in 100 μM LEV for 1 h, however, the action potential (AP), calcium influx and exocytosis were not affected. Further- more, by measuring the level of steady-state depression induced by 100 Hz stimulus trains, we found that the steady state level of depression was significantly stronger after LEV treatment, indicating that LEV enhanced short-term depression (STD). Thus, these findings suggested that the mechanisms of the antiepileptic of LEV seem to be mediated, at least partly, by regulating endocytosis and STD. 1. Introduction neuronal activity indicated that interaction of LEV with SV2A is Epilepsy is a symptom due to abnormal excessive neuronal activity likely to explain the phenomenon.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Antiepileptic Potential of Ganaxolone Antiepileptički Potencijal Ganaksolona
    Vojnosanit Pregl 2017; 74(5): 467–475. VOJNOSANITETSKI PREGLED Page 467 UDC: 615.03::616.853-085 GENERAL REVIEW https://doi.org/10.2298/VSP151221157J Antiepileptic potential of ganaxolone Antiepileptički potencijal ganaksolona Slobodan Janković, Snežana Lukić Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia Key words: Ključne reči: ganaxolone; epilepsies, partial; neurotransmitter ganaksolon; epilepsije, parcijalne; neurotransmiteri; agents; child; adult. deca; odrasle osobe. Introduction New anticonvulsants With its estimated prevalence of 0.52% in Europe, The drug resistant epilepsy has been recently defined by 0.68% in the United States of America and up to 1.5% in de- the International League Against Epilepsy as “a failure of veloping countries, epilepsy makes a heavy burden on indi- adequate trials of two tolerated, appropriately chosen and viduals, healthcare systems and societies in general all over used antiepileptic drug schedules (whether as monotherapies the world 1, 2. Despite long history of epilepsy treatment with or in combination) to achieve sustained seizure free- dom” 11.The mechanisms of drug resistance in epilepsy are medication, efficacy and effectiveness of available antiepi- still incompletely understood, and none of the anticonvul- leptic drugs as monotherapy were unequivocally proven in sants with current marketing authorization has demonstrated clinical trials only for partial-onset seizures in children and superior efficacy in the treatment of drug resistant epilepsy 12. adults (including elderly), while generalized-onset tonic- Using new anticonvulsants as add-on therapy lead to free- clonic seizures in children and adults, juvenile myoclonic dom from seizures in only 6% of patients with drug resistant epilepsy and benign epilepsy with centrotemporal spikes are epilepsy 13.
    [Show full text]
  • Synthesis and Discovery of the Putative Cognitive Enhancer BRS- 015: Effect on Glutamatergic Transmission and Synaptic Plasticity
    UCL SCHOOL OF PHARMACY BRUNSWICK SQUARE Synthesis and discovery of the putative cognitive enhancer BRS- 015: effect on glutamatergic transmission and synaptic plasticity Blanka Szulc Supervisors: Dr Stephen Hilton and Dr Arnaud Ruiz 29/07/2014 This research project is submitted in part fulfilment of the requirements for the PhD degree, UCL School of Pharmacy Department of Pharmaceutical and Biological Chemistry and the Pharmacology Department Blanka Szulc Discovery and mode of action of BRS-015 Abstract This thesis is concerned with the discovery of a novel heterocyclic compound – BRS-015, its synthesis and an analysis of its effects on excitatory synaptic transmission at a major pathway in the brain. BRS-015 is related to the natural product clausenamide, which has been shown to facilitate synaptic transmission. As such, clausenamide and related analogues may possess therapeutic potential as memory enhancing drugs, which are in urgent need of development due to the increasing numbers of patients diagnosed with memory disorders and for which there is no current effective therapy. BRS-015 was synthesized using a novel approach to the core structure of clausenamide involving an intramolecular acylal cyclisation reaction, which has not previously been reported. The first section of the thesis opens with a description of the discovery, structure and biological activity of clausenamide and discussion of previous synthetic strategies adopted by a number of research groups and attempts to classify these into the varying approaches towards the central core of clausenamide. The second section describes the structure of the rat brain and the types of processes involved in memory formation, as well as the neurophysiological assays used to investigate synaptic transmission and plasticity.
    [Show full text]
  • Seletracetam (UCB 44212)
    Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics Seletracetam (UCB 44212) Barbara Bennett,* Alain Matagne,† Philippe Michel,‡ Michèle Leonard,§ Miranda Cornet,§ Marie-Anne Meeus,¶ and Nathalie Toublanc¶ *CNS Clinical Development, UCB Atlanta, Smyrna, Georgia 30080; †Preclinical CNS, ‡Chemistry, §Non-clinical Development, and ¶Clinical Pharmacology, UCB Braine-l’Alleud, Belgium Summary: Better pharmacotherapies for epilepsy are needed demonstrates low plasma protein binding (Ͻ10%), which sug- for patients who are refractory to or have tolerability difficulties gests a low potential for drug–drug interactions. Initial studies with current treatments. Seletracetam, a new drug in epilepsy in humans demonstrated first-order monocompartmental kinet- development, is a pyrrolidone derivative structurally related to ics with a half-life of 8 h and an oral bioavailability of Ͼ90%. levetiracetam (trade name Keppra). It was discovered because Studies in healthy volunteers showed that the treatment emer- of its high binding affinity to the synaptic vesicle 2A (SV2A) gent adverse events were of mild to moderate severity, were protein, which is now known to be the binding site for this mostly of CNS origin and were resolved within 24 h. Alto- family of compounds. Seletracetam shows very potent seizure gether, these results suggest that seletracetam represents a suppression in models of acquired or genetic epilepsy, as well promising new antiepileptic drug candidate, one that demon- as high CNS tolerability in various animal models. Pharmaco- strates a potent, broad spectrum of seizure protection and a high kinetic studies in animals suggest that seletracetam is rapidly CNS tolerability in animal models, with initial clinical findings and highly absorbed, with linear and time-independent phar- suggestive of straightforward pharmacokinetics and good tol- macokinetics.
    [Show full text]